Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/29481
Title: The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
Authors: 
Keywords: 
Issue Date: 15-Mar-2018
Citation: Cancer.2018 Mar;(124)6:1197-1206
Abstract: The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated that prostate-specific antigen (PSA) screening significantly reduced prostate cancer mortality (rate ratio, 0.79; 95% confidence interval, 0.69-0.91). The US Prostate, Lung, Colorectal, and Ovarian (PLCO) trial indicated no such reduction but had a wide 95% CI (rate ratio for prostate cancer mortality, 1.09; 95% CI, 0.87-1.36). Standard meta-analyses are unable to account for key differences between the trials that can impact the estimated effects of screening and the trials' point estimates.
PMID: 29211316
URI: https://hdl.handle.net/20.500.12530/29481
Rights: openAccess
Appears in Collections:Hospitales > H. U. Infanta Cristina > Artículos

Files in This Item:
File Description SizeFormat 
PMC5839977.pdf235.87 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.